EXTEDO, a leading provider of Regulatory Information Management solutions (RIMS) for the life sciences industry, today announced its partnership with Jiaxing Taimei Medical Technology Co., Ltd., a leading SaaS-based cloud solution provider in life sciences. With deep knowledge in the areas of clinical research and pharmacovigilance, Taimei provides an extensive range of innovative IT systems and professional services.
With the latest Center for Drug Evaluation (CDE) announcement that eCTD will become mandatory across China in 2018, it is vital that EXTEDO’s customers have the best possible local support. “Besides our own office in Shanghai and our successful partnership with Neotrident China, our new partnership with Taimei Medical is another important milestone on the road to fulfilling the complex market requirements in China”, said Martin Schmid, CEO at EXTEDO.
Taimei will support EXTEDO’s solutions in the capacity of a Professional Partner. They will promote EXTEDO’s solutions in China and will provide professional technical, consulting and implementation services for local Life Sciences customers.
“Together with our partners, EXTEDO will be able to address the needs of Life Science organizations within the country and deliver the necessary software, solutions, and services designed to help streamline the registration process for pharmaceutical products. EXTEDO is proud to add Taimei to our portfolio of leading partnerships”, said Christian Bohrmann, VP Marketing & Alliances at EXTEDO.
About Jiaxing Taimei Medical Technology
Taimei comes with extensive experience, collaborating with over 200 local and global life science companies and CROs to meet the increasingly complicated regulatory requirements in China. This is made possible by a multidisciplinary team of 300 employees, 40% of whom with solid working experience within the healthcare industry. Taimei provides high-quality professional services based on innovative technologies that reduce human labor and enhance efficiency, with the aim of helping clients optimize their value across life science product lifecycles.
With the latest Center for Drug Evaluation (CDE) announcement that eCTD will become mandatory across China in 2018, it is vital that EXTEDO’s customers have the best possible local support. “Besides our own office in Shanghai and our successful partnership with Neotrident China, our new partnership with Taimei Medical is another important milestone on the road to fulfilling the complex market requirements in China”, said Martin Schmid, CEO at EXTEDO.
Taimei will support EXTEDO’s solutions in the capacity of a Professional Partner. They will promote EXTEDO’s solutions in China and will provide professional technical, consulting and implementation services for local Life Sciences customers.
“Together with our partners, EXTEDO will be able to address the needs of Life Science organizations within the country and deliver the necessary software, solutions, and services designed to help streamline the registration process for pharmaceutical products. EXTEDO is proud to add Taimei to our portfolio of leading partnerships”, said Christian Bohrmann, VP Marketing & Alliances at EXTEDO.
About Jiaxing Taimei Medical Technology
Taimei comes with extensive experience, collaborating with over 200 local and global life science companies and CROs to meet the increasingly complicated regulatory requirements in China. This is made possible by a multidisciplinary team of 300 employees, 40% of whom with solid working experience within the healthcare industry. Taimei provides high-quality professional services based on innovative technologies that reduce human labor and enhance efficiency, with the aim of helping clients optimize their value across life science product lifecycles.
